CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing Post author: Post published:December 4, 2023 Post category:uncategorized CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH). You Might Also Like Celastrol reduces cholestatic liver injury by inhibiting specific protein September 17, 2026 Vanderbilt receives $3.3 million grant to develop medications for preventing preterm birth November 17, 2024 Study: Nursing homes most adversely affected by employment declines since the pandemic November 4, 2023
Vanderbilt receives $3.3 million grant to develop medications for preventing preterm birth November 17, 2024
Study: Nursing homes most adversely affected by employment declines since the pandemic November 4, 2023